Advertisement
Screener

VERTEX PHARMACEUTICALS INC / MA (VRTX) Increase (Decrease) in Income Taxes Payable

2.8 / 5 stars · 68/120 Roast Me

VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Income Taxes Payable

VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Income Taxes Payable of -$11.36 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-01.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2013-03-01

  • VERTEX PHARMACEUTICALS INC / MA increase (decrease) in income taxes payable for the quarter ending 2012-12-31 was -$3.16M, a 236.03% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA increase (decrease) in income taxes payable for the quarter ending 2012-09-30 was $3.67M.
  • VERTEX PHARMACEUTICALS INC / MA increase (decrease) in income taxes payable for the quarter ending 2012-06-30 was $0.00.
  • VERTEX PHARMACEUTICALS INC / MA increase (decrease) in income taxes payable for the quarter ending 2012-03-31 was -$11.87M.
  • VERTEX PHARMACEUTICALS INC / MA increase (decrease) in income taxes payable for fiscal 2012 was -$11.36M, a 194.08% decline from fiscal 2011.
  • VERTEX PHARMACEUTICALS INC / MA increase (decrease) in income taxes payable for fiscal 2011 was $12.07M.
  • VERTEX PHARMACEUTICALS INC / MA increase (decrease) in income taxes payable for fiscal 2010 was $0.00.
Period endIncrease (Decrease) in Income Taxes Payable 3 monthIncrease (Decrease) in Income Taxes Payable 6 monthIncrease (Decrease) in Income Taxes Payable 9 monthIncrease (Decrease) in Income Taxes Payable 12 month
2012-12-31-$3.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01
$514.00K
derived: sum of 2 quarters · filed 2013-03-01
$514.00K
derived: sum of 3 quarters · filed 2013-03-01
-$11.36M
10-K · filed 2013-03-01
2012-09-30$3.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
$3.67M
derived: sum of 2 quarters · filed 2012-11-06
-$8.20M
10-Q · filed 2012-11-06
-$5.88M
derived: sum of 4 quarters · filed 2013-03-01
2012-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08
-$11.87M
10-Q · filed 2012-08-08
-$9.55M
derived: sum of 3 quarters · filed 2013-03-01
-$15.01M
derived: sum of 4 quarters · filed 2013-03-01
2012-03-31-$11.87M
10-Q · filed 2012-05-10
-$9.55M
derived: sum of 2 quarters · filed 2013-03-01
-$15.01M
derived: sum of 3 quarters · filed 2013-03-01
2011-12-31$2.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01
-$3.14M
derived: sum of 2 quarters · filed 2013-03-01
$12.07M
10-K · filed 2013-03-01
2011-09-30-$5.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
$9.76M
10-Q · filed 2012-11-06
2011-06-30$15.21M
10-Q · filed 2012-08-08
2010-12-31$0.00
10-K · filed 2013-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64